Par Pharmaceuticals
https://www.parpharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Par Pharmaceuticals
Endo Launches First US Mitigare Generic Following Micro Labs Lawsuit
Endo’s Par has moved on the first FDA-approved generic version of Hikma’s Mitigare prevention of gout flares – weeks after another ANDA sponsor, Micro Labs, sought to clear its own path to market via a lawsuit.
Strides Fights COVID-19-Led Sales Slump With Endo Assets, Sputnik V
After a COVID-19-led manufacturing halt at its India facility and a slowdown in US launches hit Strides during the first quarter of FY22, the Indian firm is trying to fight back with an acquisition of assets from Endo and a growth strategy for Stelis Biopharma’s vaccines business, led by Sputnik V.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice